Quality Investor
MarketsPortfolioEvidenceTestedCompareWatchlistAbout 

InfuSystem Holdings, Inc.

Rank #16Capital ReturnWatchlistCompare with other stocks

INFU · NYSE · Healthcare

InfuSystem Holdings, Inc. (INFU) — Rank #16 by gross profitability (GP/assets 0.82) · ROE 11.2% · Piotroski F-Score 8 / 9.

As-of 2026-10-30 · CIK 0001337013 · all metrics point-in-time as of the filing date.

About

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada.

Show more

It operates through two segments: Patient Services and Device Solutions. The company supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. It also sells and rents new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, the company offers local and field-based customer support, as well as operates pump service and repair centers.

The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

Industry
Medical Devices
Sector
Healthcare
State
DE
Filer Category
Accelerated filerSmaller reporting company
Fiscal Year End
December 31

Company Snapshot

P/E and reverse DCF are the primary valuation lenses at this stage.

Market Cap

—

P/E (annual)

—

P/S (annual)

—

P/B

—

P/OCF (annual)

—

Shareholder Yield

—

Employees

461

Industry

Medical Devices

Exchange

NYSE

12/12

Flags passed

INFU passes 12/12 quality flags

  • PASS
    Gross margin holding
  • PASS
    Dilution within 2%
  • PASS
    FCF not negative from investment
  • PASS
    Disclosure consistent
  • PASS
    Revenue not declining
  • PASS
    Operating margin holding
  • PASS
    Free cash flow intact
  • PASS
    Passes safety gate
  • PASS
    Balance sheet stable
  • PASS
    No competitive retreat
  • PASS
    SBC not compressing margin
  • PASS
    No valuation convergence

Strengths Operating leverage expanding · Sequential beat (rev + EPS)

A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.

Quality Profile

Profitability

1/1 pass
GP / assets
0.82
Return on equity
11.2%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
0.65
Current ratio
2.50×
Net cash
-$19.46M

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue
3.0%

Growth

2/2 pass
Revenue growth
6.4%
Piotroski F-Score
8 / 9
Share dilution
-2.8%

FCF yield, shareholder yield, and buyback activity are the primary reads at this stage.

Profitability

Does it make money well?

No warning flags · GP/assets 89th percentile of 20 SIC 3841 peers

Gross profitability (GP / assets)

0.82

Primary signal (Novy-Marx).

89th pctl of 20 SIC 3841 peers

Return on equity

11.2%

Gross margin

56.0%

21st pctl of 20 SIC 3841 peers

Revenue growth (YoY)

6.4%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2022202320242025
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

9.3%

Revenue CAGR (5Y)

8.1%

Earnings CAGR (3Y)

616.7%

FCF CAGR (3Y)

13.0%

Cash Flow Health

Is the cash real?

No warning flags · FCF 260% above net income

Free cash flow

$23.85M

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF vs net income

259.9%

(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.

FCF not below net income

Fails when free cash flow is below net income (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

3.0%

Stock-based comp intensity.

Balance Sheet Strength

Can it survive a storm?

No warning flags · net debt $19.46M, F-Score 8/9

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

0.65

10th of 19 SIC 3841 peers (best = lowest)

Current ratio

2.50×

42nd pctl of 20 SIC 3841 peers

Quick ratio

1.84×

Net cash

-$19.46M

Cash & equivalents minus total debt.

Piotroski F-Score

8 / 9

Fundamental-strength score (0-9).

Valuation

Is the price reasonable?

No warning flags

Capital allocation quality

Composite score

4.0 / 5

Strong
Share count trend(net buybacks)
-2.8%4/5 Strong
Buyback timing
N/AN/A
Dividend growth consistency(non-payer or broken streak)
0 yr3/5 Good
Net debt trajectory(deleveraging)
6.9%5/5 Strong

Lifecycle Phase History

20202025
Hypergrowth
Value
Capital Return
Op. Leverage

Price History

INFU-7.8% · -1.6% CAGRSPY+82.9% · +12.8% CAGR

View full financial statements →

Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports